Introduction - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.
Session:
PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities
Topic:
Lipids
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Amgen, Pfizer and Sanofi - Regeneron
Event:
ESC Congress 2016
Congress Presentation
About the speakers
Professor Wolfgang Koenig
German Heart Center of Munich, Munich (Germany)
24
presentations
0
follower
Professor Kausik K Ray
Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
77
presentations
11
followers
4 more presentations in this session
PCSK9, the short track road from discovery as drug target towards the clinic.
Speaker: Professor G. Lambert (SAINT DENIS, RE)
A clinical perspective on PCSK9 inhibition: what do we know and what can we expect?
Speaker: Doctor P. Ridker (Boston, US)
Preparing for a novel era in CV prevention: where do PCSK9 inhibitors fit in lipid management?
Speaker: Professor J. Kastelein (Amsterdam, NL)
Discussion & summary - PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities.
Speaker: Professor W. Koenig (Munich, DE) Professor K. Ray (London, GB)
Access the full session
PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities
Speakers:
Professor W. Koenig, Professor K. Ray, Professor G. Lambert, Doctor P. Ridker, Professor J. Kastelein...
About the event
ESC 365 is supported by
